BioLineRx and Hemispherian Unveil Promising Results for GLIX1 at SNO 2026
BioLineRx and Hemispherian Present Clinical Insights on GLIX1 at SNO 2026
In a recent presentation at the esteemed Society for Neuro-Oncology (SNO) Annual Meeting in 2026, BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS unveiled crucial findings from their ongoing Phase 1/2a clinical study of GLIX1. This novel treatment, aimed at tackling glioblastoma (GBM), has shown promising results across various models, raising hopes for patients with this aggressive form of cancer.
Advancements in the Phase 1/2a Study
The study, which is designed to evaluate the safety and effectiveness of GLIX1, commenced its fourth cohort, focusing on patients in a